Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation

被引:193
|
作者
Marsh, Rebecca A. [1 ]
Vaughn, Gretchen [1 ]
Kim, Mi-Ok [2 ]
Li, Dandan [2 ]
Jodele, Sonata [1 ]
Joshi, Sarita [1 ]
Mehta, Parinda A. [1 ]
Davies, Stella M. [1 ]
Jordan, Michael B. [1 ,3 ]
Bleesing, Jack J. [1 ]
Filipovich, Alexandra H. [1 ]
机构
[1] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH 45229 USA
[2] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA
[3] Cincinnati Childrens Hosp Med Ctr, Div Immunol, Cincinnati, OH 45229 USA
关键词
LINKED LYMPHOPROLIFERATIVE DISEASE; BONE-MARROW-TRANSPLANTATION; SINGLE-CENTER REPORT; VERSUS-HOST-DISEASE; CHIMERISM; GVHD;
D O I
10.1182/blood-2010-04-282392
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent experience suggests that reduced-intensity conditioning (RIC) regimens can improve the outcomes of patients with hemophagocytic lymphohistiocytosis (HLH) undergoing allogeneic hematopoietic cell transplantation (HCT). However, studies directly comparing RIC to myeloablative conditioning (MAC) regimens are lacking. Forty patients with HLH underwent allogeneic HCT between 2003-2009 at Cincinnati Children's Hospital. Fourteen patients received MAC consisting of busulfan, cyclophosphamide, and antithymocyte globulin plus or minus etoposide. Twenty-six patients received RIC consisting of fludarabine, melphalan, and alemtuzumab. All patients engrafted. Acute graft-versus-host disease grades II to III occurred in 14% of MAC patients and 8% of RIC patients (P = .3171). Posttransplantation mixed donor/recipient chimerism developed in 18% of MAC patients and 65% of RIC patients (P = .0110). The majority of patients with mixed chimerism received intervention with reduction of immune suppression plus or minus donor lymphocyte infusion or stem cell boost, which stabilized or increased donor contribution to hematopoiesis and prevented relapse of HLH in all but 1 patient. Grade II to III graft-versus-host disease occurred in 5 of 14 RIC patients after donor lymphocyte infusion. The overall estimated 3-year survival after HCT was 43% (confidence interval = +/- 26%) for MAC patients and 92% (confidence interval = +/- 11%) for RIC patients (P = .0001). We conclude that RIC significantly improves the outcome of patients with HLH undergoing allogeneic HCT. (Blood. 2010;116(26):5824-5831)
引用
收藏
页码:5824 / 5831
页数:8
相关论文
共 50 条
  • [41] Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen
    Delgado, Julio
    Marco, Ana
    Moreno, Estela
    Pinana, Jose L.
    Valcarcel, David
    Parody, Rocio
    Sanchez-Gonzalez, Blanca
    Martino, Rodrigo
    Briones, Javier
    Sureda, Anna
    Brunet, Salut
    Sierra, Jorge
    BLOOD, 2007, 110 (11) : 306B - 306B
  • [42] Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen
    Delgado, J.
    Marco, A.
    Moreno, E.
    Pinana, J. L.
    Valcarcel, D.
    Martino, R.
    Briones, J.
    Sureda, A.
    Brunet, S.
    Sierra, J.
    CYTOTHERAPY, 2009, 11 (03) : 356 - 361
  • [43] Comparison of Reduced-Intensity Conditioning Regimens Used in Patients Undergoing Hematopoietic Stem Cell Transplantation for Myelofibrosis
    Jain, Tania
    Temkit, M'hamed
    Partain, Daniel K.
    Patnaik, Mrinal S.
    Slack, James L.
    Khera, Nandita
    Hogan, William J.
    Roy, Vivek
    Noel, Pierre
    Leis, Jose
    Sproat, Lisa Z.
    Fauble, Veena
    Mesa, Ruben A.
    Palmer, Jeanne
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S280 - S281
  • [44] Transplantation tolerance in allogeneic stem cell transplantation with reduced-intensity conditioning
    Laylor, R
    Dyson, P
    Dewchand, H
    Simpson, E
    Dazzi, F
    BONE MARROW TRANSPLANTATION, 2004, 33 : S74 - S75
  • [45] Allogeneic stem cell transplantation with reduced-intensity conditioning in patients with relapsed lymphoma
    Rivas, M.
    Berro, M.
    Belaustegui, S.
    Prates, V.
    Yantorno, S.
    Milone, J.
    Remaggi, G.
    Rolon, J. Martinez
    Milone, G.
    Basquiera, A.
    Garcia, J.
    Sturich, G.
    Kusminsky, G.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S257 - S258
  • [46] Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia
    Chhabra, Saurabh
    Ahn, Kwang Woo
    Hu, Zhen-Huan
    Jain, Sandeep
    Assal, Amer
    Cerny, Jan
    Copelan, Edward A.
    Daly, Andrew
    DeFilipp, Zachariah
    Gadalla, Shahinaz M.
    Gale, Robert Peter
    Ganguly, Siddhartha
    Hamilton, Betty K.
    Hildebrandt, Gerhard Carl
    Hsu, Jack W.
    Inamoto, Yoshihiro
    Kanate, Abraham S.
    Khoury, H. Jean
    Lazarus, Hillard M.
    Litzow, Mark R.
    Nathan, Sunita
    Olsson, Richard F.
    Pawarode, Attaphol
    Ringden, Olle
    Rowe, Jacob M.
    Saad, Ayman
    Savani, Bipin N.
    Schouten, Harry C.
    Seo, Sachiko
    Shah, Nirav N.
    Solh, Melhem
    Stuart, Robert K.
    Ustun, Celalettin
    Woolfrey, Ann E.
    Yared, Jean A.
    Alyea, Edwin P.
    Kalaycio, Matt E.
    Popat, Uday
    Sobecks, Ronald M.
    Saber, Wael
    BLOOD ADVANCES, 2018, 2 (21) : 2922 - 2936
  • [47] CURRENT OUTCOMES OF REDUCED-INTENSITY CONDITIONING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH SAP DEFICIENCY AND XIAP DEFICIENCY
    Marsh, R. A.
    Bleesing, J. J.
    Jordan, M. B.
    Davies, S. M.
    Filipovich, A. H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S302 - S302
  • [48] Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning
    Ringden, Olle
    Brazauskas, Ruta
    Wang, Zhiwei
    Ahmed, Ibrahim
    Atsuta, Yoshiko
    Buchbinder, David
    Burns, Linda J.
    Cahn, Jean-Yves
    Duncan, Christine
    Hale, Gregory A.
    Halter, Joerg
    Hayashi, Robert J.
    Hsu, Jack W.
    Jacobsohn, David A.
    Kamble, Rammurti T.
    Kamani, Naynesh R.
    Kasow, Kimberly A.
    Khera, Nandita
    Lazarus, Hillard M.
    Loren, Alison W.
    Marks, David I.
    Myers, Kasiani C.
    Ramanathan, Muthalagu
    Saber, Wael
    Savani, Bipin N.
    Schouten, Harry C.
    Socie, Gerard
    Sorror, Mohamed L.
    Steinberg, Amir
    Popat, Uday
    Wingard, John R.
    Mattsson, Jonas
    Majhail, Navneet S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (11) : 1777 - 1784
  • [49] Histology and Time to Progression Predict Survival for Lymphoma Recurring after Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation
    Ram, Ron
    Gooley, Ted A.
    Maloney, David G.
    Press, Oliver W.
    Pagel, John M.
    Petersdorf, Stephen H.
    Shustov, Andrei R.
    Flowers, Mary E. D.
    O'Donnell, Paul
    Sandmaier, Brenda M.
    Storb, Rainer F.
    Gopal, Ajay K.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (10) : 1537 - 1545
  • [50] 400 cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation
    Sobecks, R. M.
    Dean, R.
    Rybicki, L. A.
    Chan, J.
    Theil, K. S.
    Macklis, R.
    Andresen, S.
    Kalaycio, M.
    Pohlman, B.
    Ferraro, C.
    Cherni, K.
    Sweetenham, J.
    Copelan, E.
    Bolwell, B. J.
    BONE MARROW TRANSPLANTATION, 2008, 42 (11) : 715 - 722